CHMP Safety Working Party’s response to the Paediatric Committee regarding the use of PEGylated drug products in the paediatric population

  • Email
  • Help
Current version


Reference numberEMA/CHMP/SWP/647258/2012
KeywordsPolyethylene glycol, parenteral administration, ependymal cellular vacuolation
DescriptionThis document addresses the risk for ependymal cell vacuolationuse after the use of PEGylated medicinal products in paediatric pupulation. It gives recommendations on the conduct of clinical trials with PEGylated drug products.

How helpful is this page?

Average rating:

 Based on 10 ratings

Add your rating:

See all ratings
2 ratings
2 ratings
2 ratings
2 ratings
2 ratings

Tell us more